Medigen Vaccine Biologics 대차 대조표 상태

재무 상태 기준 확인 6/6

Medigen Vaccine Biologics 의 총 주주 지분은 NT$3.9B 이고 총 부채는 NT$23.0M, 이는 부채 대 자기자본 비율을 0.6% 로 가져옵니다. 총자산과 총부채는 각각 NT$4.3B 및 NT$456.9M 입니다.

주요 정보

0.6%

부채 비율

NT$23.05m

부채

이자 보상 비율	n/a
현금	NT$1.76b
주식	NT$3.86b
총 부채	NT$456.88m
총 자산	NT$4.32b

최근 재무 상태 업데이트

We're Hopeful That Medigen Vaccine Biologics (GTSM:6547) Will Use Its Cash Wisely

Mar 31

Would Medigen Vaccine Biologics (GTSM:6547) Be Better Off With Less Debt?

Dec 15

Recent updates

We're Hopeful That Medigen Vaccine Biologics (GTSM:6547) Will Use Its Cash Wisely

Mar 31

Would Medigen Vaccine Biologics (GTSM:6547) Be Better Off With Less Debt?

Dec 15

재무 상태 분석

단기부채: 6547 의 단기 자산 ( NT$2.5B )이 단기 부채( NT$199.9M ).

장기 부채: 6547 의 단기 자산( NT$2.5B )이 장기 부채( NT$257.0M ).

부채 대 자본 내역 및 분석

부채 수준: 6547 총 부채보다 더 많은 현금을 보유하고 있습니다.

부채 감소: 6547 의 부채 대 자기자본 비율은 지난 5년간 37.5% 에서 0.6% 로 감소했습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: 6547 현재 무료 현금 흐름을 기준으로 3년 이상 충분한 현금 활주로를 보유하고 있습니다.

예측 현금 활주로: 무료 현금 흐름이 매년 1.3 %의 역사적 비율로 계속 감소한다면 6547 ) 3년 이상 충분한 현금 활주로를 보유하고 있습니다.

Medigen Vaccine Biologics 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

We're Hopeful That Medigen Vaccine Biologics (GTSM:6547) Will Use Its Cash Wisely

Would Medigen Vaccine Biologics (GTSM:6547) Be Better Off With Less Debt?

Recent updates

Medigen Vaccine Biologics Corporation to Report Q3, 2024 Results on Nov 04, 2024

Medigen Vaccine Biologics Corporation to Report Q2, 2024 Results on Aug 01, 2024

Less than half of directors are independent

Medigen Vaccine Biologics Corporation to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings released: NT$3.53 loss per share (vs NT$4.56 loss in FY 2022)

Medigen Vaccine Biologics Corporation, Annual General Meeting, Jun 13, 2024

First half 2023 earnings released: NT$1.61 loss per share (vs NT$1.41 loss in 1H 2022)

Medigen Vaccine Biologics Corporation Withdraws Covid-19 Vaccine Provisional Application and Update with Three-Dose Data for Further Review

Medigen Vaccine Biologics Corporation Approves the Election of Ming-Yi ,Wu as Independent Director and Member of Audit and Remuneration Committees

Medigen Vaccine Biologics Corporation Files New Drug Application of MVC EV71 Vaccine (Envacgen) to Drug Administration of Vietnam

Less than half of directors are independent

Less than half of directors are independent

Medigen Vaccine Biologics Corporation Announces Results of MVC COVID-19 Vaccine Phase 3 Clinical Trial in Thailand

Third quarter 2022 earnings released: NT$0.95 loss per share (vs NT$2.16 profit in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: NT$0.97 loss per share (vs NT$0.57 loss in 2Q 2021)

Now 20% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Now 20% undervalued after recent price drop

MVC File Provisional Approval Application of COVID-19 Vaccine to Therapeutic Goods Administration

First quarter 2022 earnings released: NT$0.66 loss per share (vs NT$0.74 loss in 1Q 2021)

Medigen Vaccine Biologics Corporation Announces Update on Clinical Development on MVC Covid-19 Vaccine

Less than half of directors are independent

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Bluewillow Biologics and Medigen Vaccine Biologics Announce Positive Results for Intranasal Covid-19 Booster Candidate in Pre-Clinical Studies

Medigen Vaccine Biologics Corporation Files New Drug Application (NDA) of MVC Quadrivalent Influenza Vaccine to Taiwan Food and Drug Administration

Third quarter 2021 earnings released: EPS NT$3.20 (vs NT$0.98 loss in 3Q 2020)

Medigen Vaccine Biologics Corporation and Dynavax Technologies Corporation Announces Launch of Its Covid-19 Vaccine Mvc-Cov1901 Adjuvanted with Dynavax's Cpg 1018 Adjuvant

Second quarter 2021 earnings released: NT$0.84 loss per share (vs NT$0.93 loss in 2Q 2020)

First quarter 2021 earnings released: NT$0.74 loss per share (vs NT$0.75 loss in 1Q 2020)

We're Hopeful That Medigen Vaccine Biologics (GTSM:6547) Will Use Its Cash Wisely

New 90-day high: NT$112

Medigen Vaccine Biologics Corporation Vaccine Biologics COVID-19 Vaccine Adjuvanted with Dynavax's CpG 1018 Announces First Participant Dosed in Phase 2 Clinical Trial in Taiwan

Metronic Global Berhad Provides Update on Termination of MOA with Medigen Vaccine Biologics Corporation to Obtain Exclusive Distribution Rights for MVC’s COVID-19 Vaccine

New 90-day high: NT$110

Would Medigen Vaccine Biologics (GTSM:6547) Be Better Off With Less Debt?

New 90-day high: NT$107

Metronic Global Berhad Announces Memorandum of Agreement with Medigen Vaccine Biologics Corporation

Medigen Vaccine Biologics Corporation and BlueWillow Biologics, Inc. Partners to Develop Intranasal Vaccine for SARS-CoV-2

Medigen Vaccine Biologics Corporation COVID-19 Vaccine Combined with Dynavax Technologies Corporation CpG 1018 Adjuvant Receives Taiwan Government Subsidy with First Participant Dosed in Early October

New 90-day low: NT$89.40

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

현금 런웨이 분석

건강한 기업 발견하기